How should anaemia be managed in pre-dialysis patients?

被引:24
作者
Levin, A [1 ]
机构
[1] Univ British Columbia, St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada
关键词
anaemia; blood pressure; epoetin; iron deficiency; pre-dialysis; renal function;
D O I
10.1093/ndt/14.suppl_2.66
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Anaemia is a common problem in patients with renal failure, whether or not they are on dialysis. There is a continuum of declining. renal function. In addition, the creatinine clearance at which dialysis is initiated varies widely between institutions and between studies. The term 'progressive renal insufficiency' is therefore preferable to 'pre-dialysis. The adverse effects of renal anaemia on left ventricular mass become apparent early in the course of progressive renal insufficiency: 75% of patients starting dialysis already have left ventricular hypertrophy (LVH). Correction of anaemia in patients with progressive renal insufficiency has been shown to improve physical function and anaemia-related symptoms, but no controlled studies have yet been conducted to determine its effects on LVH. Although one animal study generated some concern that epoetin may exacerbate a decline in renal function. there is no evidence from human studies for any such effect. Treatment of anaemia with epoetin in anaemic patients with progressive renal insufficiency is therefore recommended. provided blood pressure is controlled. To date, however, there are insufficient data to determine whether normalization of haemoglobin is advisable in this patient group. Detection and correction of iron deficiency is important to achieve the full benefits of epoetin. though recommendations cannot yet be made regarding the optimum route and timing of iron supplementation in patients with progressive renal insufficiency. In these patients the role of other adjuvant therapies, such as L-carnitine, vitamin Bh, vitamin B-12 and folic acid, also requires further investigation.
引用
收藏
页码:66 / 74
页数:9
相关论文
共 50 条
[1]   RENAL-FUNCTION DURING ERYTHROPOIETIN THERAPY FOR ANEMIA IN PREDIALYSIS CHRONIC-RENAL-FAILURE PATIENTS [J].
ABRAHAM, PA ;
OPSAHL, JA ;
RACHAEL, KM ;
ASINGER, R ;
HALSTENSON, CE .
AMERICAN JOURNAL OF NEPHROLOGY, 1990, 10 (02) :128-136
[2]   LOW-DOSE OF L-CARNITINE IMPAIRS MEMBRANE FRAGILITY OF ERYTHROCYTES IN HEMODIALYSIS-PATIENTS [J].
BERARD, E ;
BARRILLON, D ;
IORDACHE, A ;
BAYLE, J ;
CASSUTOVIGUIER, E .
NEPHRON, 1994, 68 (01) :145-145
[3]  
Boran M, 1996, NEPHRON, V73, P314
[4]  
CHURCHILL DN, 1995, CLIN NEPHROL, V43, P184
[5]   EFFECT OF ERYTHROPOIETIN TREATMENT ON PHYSICAL EXERCISE CAPACITY AND ON RENAL-FUNCTION IN PREDIALYTIC UREMIC PATIENTS [J].
CLYNE, N ;
JOGESTRAND, T .
NEPHRON, 1992, 60 (04) :390-396
[6]  
Drueke TB, 1997, CLIN NEPHROL, V48, P1
[7]   RHUEPO HYPORESPONSIVENESS - WHO AND WHY [J].
DRUEKE, TB .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 :62-68
[8]  
ETHIER J, 1996, J AM SOC NEPHROL, V7, P1384
[9]   EVIDENCE FOR RENAL VASODILATION IN PREDIALYSIS PATIENTS DURING CORRECTION OF ANEMIA BY ERYTHROPOIETIN [J].
FRENKEN, LAM ;
WETZELS, JFM ;
SLUITER, HE ;
KOENE, RAP .
KIDNEY INTERNATIONAL, 1992, 41 (02) :384-387
[10]   ANEMIA LESSENS AND ITS PREVENTION WITH RECOMBINANT HUMAN ERYTHROPOIETIN WORSENS GLOMERULAR INJURY AND HYPERTENSION IN RATS WITH REDUCED RENAL MASS [J].
GARCIA, DL ;
ANDERSON, S ;
RENNKE, HG ;
BRENNER, BM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (16) :6142-6146